Arbutus to Report Fourth Quarter and Year End 2022 Financial Results and Provide Corporate Update

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

WARMINSTER, Pa., Feb. 16, 2023 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that it has scheduled its fourth quarter and year end 2022 financial results and corporate update for Thursday, March 2, 2023. The schedule for the press release and conference call/webcast are as follows:

Q4 and Year End 2022 Press Release: Thursday, March 2, 2023 at 7:30 a.m. ET
Q4 and Year End 2022 Conference Call/Webcast: Thursday, March 2, 2023 at 8:45 a.m. ET
     

To dial-in for the conference call by phone, please register using the following link: Registration Link. A live webcast of the conference call can be accessed through the Investors section of Arbutus’ website at www.arbutusbio.com.

An archived webcast will be available on the Arbutus website after the event.

About Arbutus

Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases. Our current focus areas include Hepatitis B virus (HBV), SARS-CoV-2, and other coronaviruses. To address HBV, we are developing a RNAi therapeutic, an oral PD-L1 inhibitor, and an oral RNA destabilizer to potentially identify a combination regimen with the aim of providing a functional cure for patients with chronic HBV by suppressing viral replication, reducing surface antigen and reawakening the immune system. We believe our lead compound, AB-729, is the only RNAi therapeutic with evidence of immune re-awakening. It is currently being evaluated in multiple phase 2 clinical trials. We also have an ongoing drug discovery and development program directed to identifying novel, orally active agents for treating coronavirus (including SARS-CoV-2). In addition, we are exploring oncology applications for our internal PD-L1 portfolio. For more information, visit www.arbutusbio.com.

Contact Information

Investors and Media

William H. Collier
President and CEO
Phone: 267-469-0914
Email: ir@arbutusbio.com

Lisa M. Caperelli
Vice President, Investor Relations
Phone: 215-206-1822
Email: lcaperelli@arbutusbio.com

Staff

Recent Posts

Santiam Hospital and Clinics enters into Prime Vendor agreement with Medline

Oregon-based hospital taps into Medline's custom pack capabilities and distribution services NORTHFIELD Ill., June 9,…

10 hours ago

20/20NOW Advances Tele-Optometry with New VP of Professional Services Dr. Noelle Tchang OD and Spotlights Telehealth at Digital EyeCon

HOLBROOK, N.Y., June 9, 2025 /PRNewswire/ -- 20/20NOW, a pioneer in ocular telehealth, proudly announces…

10 hours ago

Business Integra Launches Mission-Ready Healthcare Staffing Solutions Backed by AI Technology

BETHESDA, Md., June 9, 2025 /PRNewswire/ -- Business Integra (BI), a leader in mission-critical talent solutions,…

10 hours ago

Imre Introduces the AI Conversation Converter

Agency launches First-in-Kind platform to quickly insert healthcare brands directly into the AI conversation NEW…

10 hours ago

Health-E Commerce® expands telehealth offerings with LifeMD™ to provide sleep treatments via FSA Store® and HSA Store®

New collaboration delivers 50% off prescription sleep support for new customers who are struggling with…

16 hours ago